文献速递血管炎

吗替麦考酚酯与环磷酰胺诱导ANCA相关血管炎缓解的非劣效随机试验

Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial.
PubMed 文献 · Ann Rheum Dis · 2019-01-05

该随机对照试验纳入140例新诊断ANCA相关血管炎患者,比较吗替麦考酚酯(MMF)与间断环磷酰胺诱导缓解的非劣效性。6个月缓解率MMF组67%、环磷酰胺组61%,非劣效性成立;但缓解后MMF组复发更多(33% vs 19%)。

要点

  • MMF诱导缓解非劣效于环磷酰胺,6个月缓解率67% vs 61%。
  • 缓解后MMF组复发率更高(33% vs 19%),PR3-ANCA者差异明显。
  • 严重感染两组相似(26% vs 17%),eGFR<15 mL/min者被排除。

核心结论

  • MMF在AAV诱导缓解方面非劣效于环磷酰胺,但缓解后复发率更高。

研究设计与样本

  • 随机对照非劣效试验,纳入140例新诊断AAV患者,随机分配至MMF或间断环磷酰胺组,均接受相同口服糖皮质激素方案,缓解后换用硫唑嘌呤。

主要发现

  • 6个月主要缓解终点MMF组47例(67%),环磷酰胺组43例(61%),风险差5.7%(90%CI -7.5%至19%)。
  • 缓解后复发MMF组23例(33%),环磷酰胺组13例(19%),发生率比1.97(95%CI 0.96至4.23,p=0.049)。
  • MPO-ANCA患者复发率环磷酰胺组12%、MMF组15%;PR3-ANCA患者环磷酰胺组24%、MMF组48%。
  • 严重感染MMF组26%、环磷酰胺组17%(OR 1.67,95%CI 0.68至4.19,p=0.3)。

关键数值与推荐

  • 主要终点为6个月内缓解且符合糖皮质激素减量方案。
  • 排除eGFR<15 mL/min的患者。
  • 非劣效性依据风险差5.7%(90%CI -7.5%至19%)判定。

临床怎么用

  • MMF可作为AAV诱导缓解的替代方案,但需关注缓解后复发风险,尤其PR3-ANCA患者。

局限性

  • 排除eGFR<15 mL/min患者,结果不适用于该人群。
  • 复发率差异的置信区间较宽,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Cyclophosphamide induction regimens are effective for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but are associated with infections, malignancies and infertility. Mycophenolate mofetil (MMF) has shown high remission rates in small studies of AAV. METHODS: We conducted a randomised controlled trial to investigate whether MMF was non-inferior to cyclophosphamide for remission induction in AAV. 140 newly diagnosed patients were randomly assigned to MMF or pulsed cyclophosphamide. All patients received the same oral glucocorticoid regimen and were switched to azathioprine following remission. The primary endpoint was remission by 6 months requiring compliance with the tapering glucocorticoid regimen. Patients with an eGFR <15 mL/min were excluded from the study. RESULTS: At baseline, ANCA subtype, disease activity and organ involvement were similar between groups. Non-inferiority was demonstrated for the primary remission endpoint, which occurred in 47 patients (67%) in the MMF group and 43 patients (61%) in the cyclophosphamide group (risk difference 5.7%, 90% CI -7.5% to 19%). Following remission, more relapses occurred in the MMF group (23 patients, 33%) compared with the cyclophosphamide group (13 patients, 19%) (incidence rate ratio 1.97, 95% CI 0.96 to 4.23, p=0.049). In MPO-ANCA patients, relapses occurred in 12% of the cyclophosphamide group and 15% of the MMF group. In PR3-ANCA patients, relapses occurred in 24% of the cyclophosphamide group and 48% of the MMF group. Serious infections were similar between groups (26% MMF group, 17% cyclophosphamide group) (OR 1.67, 95% CI 0.68 to 4.19, p=0.3). CONCLUSION: MMF was non-inferior to cyclophosphamide for remission induction in AAV, but resulted in higher relapse rate. TRIAL REGISTRATION NUMBER: NCT00414128.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Jones RB, Hiemstra TF, Ballarin J, et al. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Ann Rheum Dis. 2019. PMID: 30612116. doi:10.1136/annrheumdis-2018-214245

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。